Correction - Inify Laboratories: First gastrointestinal diagnoses delivered and UK clinical operations on track for launch early 2026
In connection with the publication of the company's Q3 2025 Financial Report, it was discovered that the amount for personnel costs in the parent company's income statement was incorrect. The company is therefore making a correction to the parent company's income statement.
STOCKHOLM – October 29, 2025 - Inify Laboratories, a unique laboratory service that provides cancer diagnostics within pathology, expanded its service offering during the third quarter with the addition of a second diagnostic area: gastroenterology. In September, the company launched gastrointestinal diagnostics services in Sweden, successfully diagnosing its first patient samples.
“This marks the starting point for addressing a market with very large sample volumes and enormous capacity needs. In Sweden alone, hundreds of thousands of endoscopy examinations are performed annually, many of which result in tissue sampling,” says CEO Fredrik Palm of Inify Laboratories.
Sales growth in the third quarter was strong, with an increase of 76% compared to the corresponding period last year, and 78% for the period January – September. The subsidiary Inify Laboratories Nordics continues to support expansion with its steady positive cashflow. Cash balance at the end of the period amounted to SEK 112 million.
The sales growth from gastrointestinal diagnostics is expected to build gradually from 2026 onwards.
Construction of Inify’s laboratory in Milton Park, just south of Oxford in the UK, is progressing according to plan. The goal of launching clinical operations in early 2026 remains unchanged. Dialogues with customers – primarily the NHS – also continue to progress steadily.
“We remain optimistic that agreements will be signed, enabling sales to commence through our UK subsidiary in close connection with the opening of the new laboratory,” says Palm.
Inify’s initial UK offering will focus on prostate cancer diagnostics, where most customer dialogues are already well advanced. Following the launch of gastrointestinal diagnostics in Sweden, the company will gradually introduce this area into the UK operations.
“Continued growth, expansion into a new diagnostic area, progress in our UK establishment, and clear examples of the potential in our standardised and structured data – all of this, in my view, bodes well for a bright and exciting future, with Inify taking on an increasingly prominent role in current and future healthcare,” says Palm.
For further information, please contact CEO Fredrik Palm, [email protected], or visit https://www.inify.com
###
This information is subject to the disclosure requirements pursuant to section 5 -12 of the Norwegian Securities Trading Act.
###
The future of diagnostics
Inify Laboratories offers diagnostics through specialised laboratory services in histopathology, with a focus on streamlining patient pathways. The company performs clinical diagnostics in prostate cancer and gastroenterology, providing an integrated service that spans from early sample handling to final diagnosis. The laboratory system is scalable both in handling large volumes of patient samples and for replicating in new locations.
Quality and response times are optimised in every step - from logistics to tissue preparation and diagnosis – using a fully digital, standardised and AI-assisted workflow. The diagnosis is always performed by a pathologist and is assisted by Inify's proprietary AI, proven to have world-leading precision in clinical evaluations. The entire workflow is supported by a tailor-made system that also enables development to include additional diagnostic areas.
Inify Laboratories is an international group headquartered in Solna, Sweden, with local laboratories in Sweden and the UK. The company's share is listed on Euronext Growth Oslo under the ticker INIFY.